Results 1 to 10 of about 5,411 (177)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

PLoS ONE, 2019
BACKGROUND:Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and
Nancy F Olivieri, Amir Sabouhanian, Brenda L Gallie   +2 more
doaj   +1 more source

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

Haematologica, 2011
Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and ...
Alessia Pepe, Antonella Meloni, Marcello Capra, Paolo Cianciulli, Luciano Prossomariti, Cristina Malaventura, Maria Caterina Putti, Alma Lippi, Maria Antonietta Romeo, Maria Grazia Bisconte, Aldo Filosa, Vincenzo Caruso, Antonella Quarta, Lorella Pitrolo, Massimiliano Missere, Massimo Midiri, Giuseppe Rossi, Vincenzo Positano, Massimo Lombardi, Aurelio Maggio   +19 more
doaj   +1 more source

Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases [PDF]

Trends in Pharmaceutical Sciences
Thalassemia is a genetic disease that significantly affects human health. The common treatment of thalassemia is the regular injection of red blood cell, which is associated with the accumulation of iron in different tissues of the body, and makes ...
Sara Sadeghian, Fateme Zare, Lotfollah Saghaie, Razieh Sabet   +3 more
doaj   +1 more source

Perbedaan Kadar Thyroid Stimulating Hormone dan Free Thyroxine pada Pasien Talasemia Β-Mayor dengan Kelasi Besi Deferasirox dan Deferiprone

Sari Pediatri, 2018
Latar belakang. Talasemia β Mayor merupakan kelainan herediter yang disebabkan gangguan produksi rantai globin. Transfusi rutin menyebabkan kelebihan besi yang tertimbun dalam jaringan sehingga menyebabkan kardiomiopati, gangguan liver, dan komplikasi ...
Aries - Krisbiyantoro, Harsono Salimo, Annang Giri Moelyo   +2 more
doaj   +1 more source

Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes [version 2; peer review: 2 approved]

F1000Research, 2023
Background Excess iron deriving from a chronic transfusion and dietary intake increases the risk for cardiac complications in β-thalassemia major patients.
Khairunnisa Khairunnisa, Heru Noviat Herdata, Eka Destianti Edward, Sulaiman Yusuf   +3 more
doaj   +1 more source

Chelation Combination—A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper?

Biomolecules, 2022
The chelating thiol dimercaptosuccinate (DMSA) and the traditional agent D-penicillamine (PSH) are effective in enhancing the urinary excretion of copper (Cu) and lead (Pb) in poisoned individuals. However, DMSA, PSH, EDTA (ethylenediamine tetraacetate),
Jan O. Aaseth, Valeria M. Nurchi
doaj   +1 more source

A pilot trial of deferiprone in pantothenate kinase-associated neurodegeneration patients

Neurology International, 2018
Pantothenate kinase-associated neurodegeneration (PKAN) is the most common form of neurodegeneration with brain iron accumulation, it is an autosomal recessive disease due to mutation in PANK 2 on chromosome 20, which causes the accumulation of iron in ...
Mohammad Rohani, Saeed Razmeh, Gholam Ali Shahidi, Maryam Orooji   +3 more
doaj   +1 more source

Synergistic Effects of Nanoemulsion and Deferiprone (1, 2 Dimethyl-3-Hydroxypyrid-4-One) on Multi-Drug Resistant Acinetobacter baumannii

Nano Biomedicine and Engineering, 2019
Nosocomial infections caused by Acinetobacter baumannii (A. baumannii) are exceedingly difficult to treat, particularly in immune-compromised patients. Nanoemulsions (NEs) are a distinctive category of disinfectants that have wide range of bactericidal ...
Karthikeyan Ramalingam, Valerie Lee
doaj   +1 more source

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Scientific Reports, 2017
Parkinson’s disease (PD) is associated with increased iron levels in the substantia nigra (SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelate iron from various brain regions and improve PD symptomology ...
Antonio Martin-Bastida, Roberta J. Ward, Rexford Newbould, Paola Piccini, David Sharp, Christina Kabba, Maneesh C. Patel, Michael Spino, John Connelly, Fernando Tricta, Robert R. Crichton, David T. Dexter   +11 more
doaj   +1 more source

Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series

Infectious Disease Reports, 2018
Mucormycosis is a life-threatening disease requiring multimodal treatment with antifungals and surgery. The mortality rate remains high, prompting consideration of alternative treatment strategies. Deferiprone has in vitro activity against Mucorales, but
Maria N. Chitasombat, Pimjai Niparuck
doaj   +1 more source